Their studies showed that CD44+α2β1hiCD133+ cells isolated from prostate cancer patients have a high potential for self-renewal and proliferation; these cells were also able to differentiate to heterogeneous cancer cells in ex vivo culture (Collins et al., 2005). This evidence concerns the gene CD44 and cancer.